Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.960
-0.630 (-13.73%)
At close: Nov 20, 2024, 4:00 PM
3.880
-0.080 (-2.02%)
Pre-market: Nov 21, 2024, 5:29 AM EST
Aclaris Therapeutics Employees
As of December 31, 2023, Aclaris Therapeutics had 91 total employees, including 86 full-time and 5 part-time employees. The number of employees decreased by 14 or -13.33% compared to the previous year.
Employees
91
Change (1Y)
-14
Growth (1Y)
-13.33%
Revenue / Employee
$297,571
Profits / Employee
-$406,637
Market Cap
282.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Viemed Healthcare | 996 |
Spok Holdings | 384 |
Alpha Teknova | 211 |
AVITA Medical | 207 |
CVRx, Inc. | 200 |
COMPASS Pathways | 186 |
Nano-X Imaging | 164 |
AC Immune | 161 |
ACRS News
- 1 day ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 2 days ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire
- 2 days ago - Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - GlobeNewsWire
- 2 days ago - Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - GlobeNewsWire
- 5 months ago - Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte) - GlobeNewsWire